TNF-bp: AMGN began a multicenter, double-blind, placebo-controlled Phase I trial

Amgen Inc. (AMGN), Thousand Oaks, Calif. Product: TNF-bp ( tumor necrosis factor binding protein) Indication: Rheumatoid arthritis Status: AMGN began a multicenter, double-blind, placebo-controlled Ph...